We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Third Dose of Measles-Mumps-Rubella Vaccine to Improve Immunity Against Mumps in Young Adults.
- Authors
Kaaijk, Patricia; Wijmenga-Monsuur, Alienke J; Houten, Marlies A van; Veldhuijzen, Irene K; Hulscher, Hinke I ten; Kerkhof, Jeroen; Klis, Fiona R van der; Binnendijk, Rob S van; van Houten, Marlies A; Ten Hulscher, Hinke I; van der Klis, Fiona R; van Binnendijk, Rob S
- Abstract
<bold>Background: </bold>Waning of vaccine-induced immunity is considered to play a central role in the reemergence of mumps among vaccinated young adults. The aim of the present study was to investigate antibody responses and safety of a third dose of measles-mumps-rubella vaccine (MMR-3) in 150 young adults. Antibody levels were related to a surrogate of protection based on preoutbreak serum antibody levels in 31 persons with and 715 without serological evidence of mumps.<bold>Methods: </bold>Mumps virus-specific immunoglobulin G (IgG) antibody responses and mumps virus-neutralizing antibody responses (based on the focus-reduction neutralizing test) against both the Jeryl Lynn mumps virus vaccine strain (hereafter, the "vaccine strain") and the MuVi/Utrecht.NLD/40.10 outbreak strain (hereafter, the "outbreak strain") were determined, and vaccine safety was evaluated.<bold>Results: </bold>Four weeks following MMR-3 receipt, levels of IgG, anti-vaccine strain, and anti-outbreak strain antibodies increased by a factor of 1.65, 1.34, and 1.35, respectively. Although antibody levels decreased 1 year later, they were still above the baseline level by a factor of 1.37, 1.15, and 1.27, respectively. Based on the surrogate protective antibody cutoff, significantly more participants were protected against mumps virus infection up to 1 year after vaccination (ie, they had antibody levels above the presumed threshold for herd immunity).<bold>Conclusions: </bold>MMR-3 receipt increased antibody levels that may protect against mumps virus infection for longer than previously assumed and is expected to be a good and safe intervention for controlling a mumps outbreak.<bold>Clinical Trials Registration: </bold>2016-001104-36; NTR5911.
- Subjects
MMR vaccines; MUMPS; YOUNG adults; IMMUNOGLOBULIN G; VACCINE safety; IMMUNITY; RESEARCH; IMMUNOGLOBULINS; RESEARCH methodology; EVALUATION research; MEDICAL cooperation; COMPARATIVE studies; EPIDEMICS; RECEIVER operating characteristic curves; VIRAL antibodies; LONGITUDINAL method
- Publication
Journal of Infectious Diseases, 2020, Vol 221, Issue 6, p902
- ISSN
0022-1899
- Publication type
journal article
- DOI
10.1093/infdis/jiz188